- Home
- VRNA vs CRSP Comparison
VRNA vs CRSP Comparison
Compare VRNA & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- CRSP
- Stock Information
- Founded
- VRNA 2005
- CRSP 2013
- Country
- VRNA United Kingdom
- CRSP Switzerland
- Employees
- VRNA N/A
- CRSP N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRNA Health Care
- CRSP Health Care
- Exchange
- VRNA Nasdaq
- CRSP Nasdaq
- Market Cap
- VRNA 3.4B
- CRSP 3.4B
- IPO Year
- VRNA 2017
- CRSP 2016
- Fundamental
- Price
- VRNA $51.89
- CRSP $40.53
- Analyst Decision
- VRNA Strong Buy
- CRSP Buy
- Analyst Count
- VRNA 7
- CRSP 19
- Target Price
- VRNA $50.57
- CRSP $77.13
- AVG Volume (30 Days)
- VRNA 1.4M
- CRSP 1.8M
- Earning Date
- VRNA 02-27-2025
- CRSP 02-19-2025
- Dividend Yield
- VRNA N/A
- CRSP N/A
- EPS Growth
- VRNA N/A
- CRSP N/A
- EPS
- VRNA N/A
- CRSP N/A
- Revenue
- VRNA $5,624,000.00
- CRSP $202,829,000.00
- Revenue This Year
- VRNA N/A
- CRSP N/A
- Revenue Next Year
- VRNA $550.30
- CRSP $724.16
- P/E Ratio
- VRNA N/A
- CRSP N/A
- Revenue Growth
- VRNA 1127.95
- CRSP 19.31
- 52 Week Low
- VRNA $11.39
- CRSP $36.52
- 52 Week High
- VRNA $55.42
- CRSP $91.10
- Technical
- Relative Strength Index (RSI)
- VRNA 64.25
- CRSP 44.09
- Support Level
- VRNA $43.44
- CRSP $36.52
- Resistance Level
- VRNA $55.42
- CRSP $40.99
- Average True Range (ATR)
- VRNA 3.32
- CRSP 1.78
- MACD
- VRNA 0.40
- CRSP 0.23
- Stochastic Oscillator
- VRNA 70.52
- CRSP 51.68
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.